Noteworthy Cases
A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma
Iyad Alnahhas MD, MS,
Iyad Alnahhas MD, MS
Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA
Search for more papers by this author Jason Wong MD,
Jason Wong MD
Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA
Search for more papers by this author
Iyad Alnahhas MD, MS,
Iyad Alnahhas MD, MS
Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA
Search for more papers by this author Jason Wong MD,
Jason Wong MD
Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA
Search for more papers by this author
First published: 09 December 2016
No abstract is available for this article.
REFERENCES
- 1
Zimmer L,
Goldinger SM,
Hofmann L,
Loquai C,
Ugurel S,
Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 210–225.
- 2
Brahmer JR,
Tykodi SS,
Chow LQM,
Hwu WJ,
Topalian SL,
Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455–2465.
- 3
Loochtan AI,
Nickolich MS,
Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 2015; 52: 307–308.
- 4
Shirai T,
Sano T,
Kamijo F,
Saito N,
Miyake T,
Kodaira M, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 2016; 46: 86–88.
- 5
Johnson DB,
Saranga-Perry V,
Lavin PJ,
Burnette WB,
Clark SW,
Uskavitch DR, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 2015; 33: e122–124.
- 6
Sciacca G,
Nicoletti A. Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve 2016; 54: 504–509.
- 7
Antonia SJ,
López-Martin JA,
Bendell J. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016; 17: 883–895.
- 8
Liao B,
Shroff S,
Kamiya-Matsuoka C,
Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014; 16: 589–593.
- 9
Maeda O,
Yokota K,
Atsuta N. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci 2016; 78: 119–122.
- 10
Zhu J,
Li Y. Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve 2016; 54: 506–507.
- 11
Lau KH,
Kumar A,
Yang IH,
Nowak RJ. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve 2016; 54: 157–161.
